Assessment of Treatment Effect With Multiple Outcomes in 2 Clinical Trials of Patients With Duchenne Muscular Dystrophy.
作者信息
Li Daniel, McDonald Craig M, Elfring Gary L, Souza Marcio, McIntosh Joseph, Kim Dae Hyun, Wei Lee-Jen
机构信息
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Physical Medicine and Rehabilitation, Department of Pediatrics, University of California Davis, Sacramento.
出版信息
JAMA Netw Open. 2020 Feb 5;3(2):e1921306. doi: 10.1001/jamanetworkopen.2019.21306.
Abstract
摘要
相似文献
1
Assessment of Treatment Effect With Multiple Outcomes in 2 Clinical Trials of Patients With Duchenne Muscular Dystrophy.杜氏肌营养不良症患者两项临床试验中多结局治疗效果的评估
JAMA Netw Open. 2020 Feb 5;3(2):e1921306. doi: 10.1001/jamanetworkopen.2019.21306.
2
[Duchenne muscular dystrophy].杜兴氏肌营养不良症
MMW Fortschr Med. 2015 Jul 23;157(13):81. doi: 10.1007/s15006-015-3369-7.
3
PTC124, nonsense mutations and Duchenne muscular dystrophy.PTC124、无义突变与杜氏肌营养不良症
Neuromuscul Disord. 2007 Oct;17(9-10):719-20. doi: 10.1016/j.nmd.2007.07.001.
4
European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene.欧洲药品管理局对阿他芦醇用于治疗5岁及以上因肌营养不良蛋白基因无义突变导致的杜氏肌营养不良门诊患者的审评。
Neuromuscul Disord. 2015 Jan;25(1):5-13. doi: 10.1016/j.nmd.2014.11.011. Epub 2014 Nov 24.
5
Duchenne drug clings on for FDA nod.用于治疗杜氏肌营养不良症的药物有望获得美国食品药品监督管理局批准。
Nat Biotechnol. 2017 Nov 9;35(11):999. doi: 10.1038/nbt1117-999.
6
EMA reconsiders 'read-through' drug against Duchenne muscular dystrophy following appeal.欧洲药品管理局在接到上诉后重新考虑用于治疗杜氏肌营养不良症的“通读”药物。
Nat Biotechnol. 2014 Aug;32(8):706. doi: 10.1038/nbt0814-706.
7
Duchenne muscular dystrophy.杜兴氏肌肉营养不良症
BMJ. 2020 Jan 23;368:l7012. doi: 10.1136/bmj.l7012.
8
Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy.对无义突变型杜氏肌营养不良症中阿托伦随机对照试验的荟萃分析。
J Comp Eff Res. 2020 Oct;9(14):973-984. doi: 10.2217/cer-2020-0095. Epub 2020 Aug 27.
9
10
Studies point way to new therapeutic prospects for muscular dystrophy.研究为肌肉萎缩症指明了新的治疗前景。
JAMA. 2007 Sep 26;298(12):1385-6. doi: 10.1001/jama.298.12.1385.
引用本文的文献
1
Protocol Development for Investigator-Sponsored Clinical Studies.研究者发起的临床研究的方案制定
Clin Transl Sci. 2025 May;18(5):e70237. doi: 10.1111/cts.70237.
2
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.用于杜氏肌营养不良症的腺相关病毒基因疗法：EMBARK 3期随机试验
Nat Med. 2025 Jan;31(1):332-341. doi: 10.1038/s41591-024-03304-z. Epub 2024 Oct 9.
3
Neurocognition and academic achievement among bereaved children in the Generation R Cohort.丧亲儿童的神经认知与学业成就：荷兰鹿特丹“生育队列研究”
Sci Rep. 2024 Sep 11;14(1):21187. doi: 10.1038/s41598-024-72178-5.
4
Review of neuropsychological outcomes in isolated methylmalonic acidemia: recommendations for assessing impact of treatments.孤立性甲基丙二酸血症神经认知结局的研究：治疗效果评估建议
Metab Brain Dis. 2022 Jun;37(5):1317-1335. doi: 10.1007/s11011-022-00954-1. Epub 2022 Mar 29.
5
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients.依伐布雷定改善射血分数降低心衰患者运动耐量及生活质量
J Comp Eff Res. 2022 Feb;11(3):139-155. doi: 10.2217/cer-2021-0196. Epub 2021 Nov 18.
6
Read-through approach for stop mutations in Duchenne muscular dystrophy. An update.通读方法治疗杜氏肌营养不良症中的终止突变。更新。
Acta Myol. 2021 Mar 31;40(1):43-50. doi: 10.36185/2532-1900-041. eCollection 2021 Mar.
7
[Expert recommendation: treatment of nonambulatory patients with Duchenne muscular dystrophy].[专家推荐：杜氏肌营养不良症非行走患者的治疗]
Nervenarzt. 2021 Apr;92(4):359-366. doi: 10.1007/s00115-020-01019-3. Epub 2020 Nov 19.
本文引用的文献
1
Methods for the analysis of multiple endpoints in small populations: A review.小群体中多个终点指标的分析方法：综述
J Biopharm Stat. 2019;29(1):1-29. doi: 10.1080/10543406.2018.1489402. Epub 2018 Jul 9.
2
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.依特醇治疗无义突变型杜氏肌营养不良症（ACT DMD）患者的疗效：一项多中心、随机、双盲、安慰剂对照的 3 期临床试验。
Lancet. 2017 Sep 23;390(10101):1489-1498. doi: 10.1016/S0140-6736(17)31611-2. Epub 2017 Jul 17.
3
Ataluren treatment of patients with nonsense mutation dystrophinopathy.阿他芦醇治疗无义突变型肌营养不良症患者。
Muscle Nerve. 2014 Oct;50(4):477-87. doi: 10.1002/mus.24332.
Zotero 插件